... years, with numerous new agents, including IL-4 and IL-13 pathway inhibitors as well as JAK inhibitors, reaching the market, receiving approval, or nearing the final stages of clinical development.
"The depth and durability of responses in thrombocytopenic patients who had failed or had suboptimal benefit from prior JAK inhibitor therapy are particularly encouraging and pave way for phase 2 trial.".